Clinical Trial Update: (CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. [Phase 3]

View source ↗

Summary

Extension study of Budesonide MMX 6 mg for maintenance of remission in Ulcerative Colitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Budesonide MMX 6 mg (budesonide)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-17